Literature DB >> 18462557

Association between apathy/depression and executive function in patients with Alzheimer's disease.

Shutaro Nakaaki1, Yoshie Murata, Junko Sato, Yoshihiro Shinagawa, Jin Hongo, Hiroshi Tatsumi, Nobutsugu Hirono, Masaru Mimura, Toshiaki A Furukawa.   

Abstract

BACKGROUND: Apathy and depression may be strongly associated with executive dysfunction in Alzheimer's disease (AD). The Frontal Assessment Battery (FAB) is an instrument for assessing executive function. The dual task paradigm is also useful for assessing divided attention. However, the association between apathy/depression and these tasks is unclear.
METHODS: Both the FAB and the dual task were used to evaluate AD patients. A two-way analysis of variance was then conducted between the FAB and dual task results and the absence versus the presence of depression or the absence versus the presence of apathy.
RESULTS: Of 88 patients with AD, 26 had both apathy and depression, 26 had depression only, 18 had apathy only, and 18 had neither. Total FAB scores and dual task scores differed significantly between the AD patients with depression and those without depression; the scores were also different between those with apathy and those without apathy. Also, a significant interaction between depression and apathy was noted for the total FAB and dual task scores.
CONCLUSIONS: The deficits in the total FAB and dual task scores were larger in AD patients with both apathy and depression compared with patients with either apathy or depression alone. AD patients with both symptoms may have greater deficits in frontal lobe function relative to AD patients with either apathy or depression alone.

Entities:  

Mesh:

Year:  2008        PMID: 18462557     DOI: 10.1017/S1041610208007308

Source DB:  PubMed          Journal:  Int Psychogeriatr        ISSN: 1041-6102            Impact factor:   3.878


  7 in total

1.  Neuropsychiatric symptoms in Alzheimer's disease.

Authors:  Constantine G Lyketsos; Maria C Carrillo; J Michael Ryan; Ara S Khachaturian; Paula Trzepacz; Joan Amatniek; Jesse Cedarbaum; Robert Brashear; David S Miller
Journal:  Alzheimers Dement       Date:  2011-09       Impact factor: 21.566

2.  The Roles of Apathy and Depression in Predicting Alzheimer Disease: A Longitudinal Analysis in Older Adults With Mild Cognitive Impairment.

Authors:  Myuri Ruthirakuhan; Nathan Herrmann; Danielle Vieira; Damien Gallagher; Krista L Lanctôt
Journal:  Am J Geriatr Psychiatry       Date:  2019-02-07       Impact factor: 4.105

3.  Functional connectivity correlates of reduced goal-directed behaviors in behavioural variant frontotemporal dementia.

Authors:  Valérie Godefroy; Bénédicte Batrancourt; Sylvain Charron; Arabella Bouzigues; David Bendetowicz; Guilhem Carle; Armelle Rametti-Lacroux; Stéphanie Bombois; Emmanuel Cognat; Raffaella Migliaccio; Richard Levy
Journal:  Brain Struct Funct       Date:  2022-06-25       Impact factor: 3.270

4.  Cerebral Volumetric Correlates of Apathy in Alzheimer's Disease and Cognitively Normal Older Adults: Meta-Analysis, Label-Based Review, and Study of an Independent Cohort.

Authors:  Shefali Chaudhary; Simon Zhornitsky; Herta H Chao; Christopher H van Dyck; Chiang-Shan R Li
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

Review 5.  Behavioral and psychological symptoms in Alzheimer's disease.

Authors:  Xiao-Ling Li; Nan Hu; Meng-Shan Tan; Jin-Tai Yu; Lan Tan
Journal:  Biomed Res Int       Date:  2014-07-15       Impact factor: 3.411

Review 6.  Brain mechanisms underlying neuropsychiatric symptoms in Alzheimer's disease: a systematic review of symptom-general and -specific lesion patterns.

Authors:  Yaojing Chen; Mingxi Dang; Zhanjun Zhang
Journal:  Mol Neurodegener       Date:  2021-06-07       Impact factor: 14.195

Review 7.  Neuropsychiatric Disturbances in Alzheimer's Disease: What Have We Learned from Neuropathological Studies?

Authors:  Debby Van Dam; Yannick Vermeiren; Alain D Dekker; Petrus J W Naudé; Peter P De Deyn
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.